Histosonics Initiates Clinical Trial
Ann Arbor, MI -- HistoSonics, Inc., announced today the first experimental treatment of a research subject with BPH using its Vortx RX device. The Vortx RX is based on histotripsy technology, a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues.
Urologist Timothy Schuster, MD of ProMedica Genito-Urinary Surgeons in Toledo, Ohio performed the first Vortx RX experimental treatment and notes, “Clinical trials are essential to the development of new medical technologies in order to achieve significant advancements in patient care. We are pleased to be a part of this pilot (safety) study, an important first step for histotripsy BPH treatment.”
The Vortx RX is an investigational device and is limited by law to investigational use by qualified investigators in the U.S. and Canada. Read more...
Find Out More About ESP
Mike Bunker manages the Early Stage Partners investment in Histosonics